Immune checkpoint inhibitor ‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer

ConclusionsORR and PFS were significantly better in ILD patients than in irAEs ‐non‐ILD and non‐irAEs patients. Pre‐existing history of IP was an independent risk factor for ILD‐induced ICIs.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

ConclusionsTreatment of patients with relapsed solid tumors with 7.5  mg/d E and 800 mg/d S is safe and feasible. Early metabolic response in FDG‐PET was not confirmed in CT scan several weeks later. The combination of S and E is obviously not sufficient to induce durable responses in patients with KRAS‐mutant solid tumors.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Conclusion Wrapping bronchial anastomosis with pedicled pericardial fat flap in bronchial lobectomy for centralized NSCLC is a simple and effective approach to prevent BPF, thus safety of the operation could be significantly improved. DOI: 10.3779/j.issn.1009-3419.2020.104.01
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Conclusions: Complete uniportal ALR, particularly for segmentectomy and lobectomy is safe and feasible with low complication rates and excellent free resection margin rates. SML during complete uniportal thoracoscopic surgery adequately assesses the N2 lymph node. However, further studies need to be conducted to evaluate the role of CUT-ALR-SML in the treatment of NSCLC.
Source: Surgical Laparoscopy, Endoscopy and Percutaneous Techniques - Category: Surgery Tags: Original Articles Source Type: research
Programmed cell death ‐1 immune checkpoint inhibitor (ICI) antibody has proven to be effective in advanced non‐small cell lung cancer (NSCLC) patients positive for programmed cell death‐1 ligand‐1. However, there are currently no reports which evaluate drug efficacy by continuous bronchoscopic observation. A 75‐ year‐old man with complete right atelectasis was diagnosed with squamous cell carcinoma (SCC) of the right lower lobe (tumor proportion score: TPS 90%, cT4N3M0, stage 3C). For first‐line chemotherapy, carboplatin and nab‐paclitaxel were effective for the primary lesion and the right lung atele ctasi...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
Publication date: Available online 20 February 2020Source: Acta Pharmaceutica Sinica BAuthor(s): Kudelaidi Kuerban, Xiwen Gao, Hui Zhang, Jiayang Liu, Mengxue Dong, Lina Wu, Ruihong Ye, Meiqing Feng, Li YeAbstractMore efficient drug delivery system and formulation with less adverse effects are needed for the clinical application of broad-spectrum antineoplastic agent doxorubicin (DOX). Here we obtained outer-membrane vesicles (OMVs), a nano-sized proteoliposomes naturally released by Gram-negative bacteria, from attenuated Klebsiella pneumonia and prepared doxorubicin-loaded OMVs (DOX-OMV). Confocal microscopy and in vivo ...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
CONCLUSION: Preoperative abnormal CONUT score is a poor prognostic factor for the elderly NSCLC patients with preoperative comorbidities and might predict poor postoperative outcome caused by not primary lung cancer but other diseases. PMID: 31996508 [PubMed - as supplied by publisher]
Source: Annals of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Cardiovasc Surg Source Type: research
ConclusionsDecrease in the rates of perioperative outcomes parallels improvements in patient selection and perioperative management of early stage NSCLC resection patients. Predictors of pulmonary complication could be used to improve selection criteria for surgery and to reduce the incidence of pulmonary complication in these patients.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
This study is registered with ClinicalTrials.gov (NCT02108964); enrolment to phase 1 is complete and the study is ongoing.FindingsBy Aug 31, 2017, 180 patients (116 [64%] women; median age 60 years (52–69); 116 [64%] with ECOG performance status 1) received nazartinib across seven dose levels: 75 mg (n=17), 100 mg (n=38), 150 mg (n=73), 200 mg (n=8), 225 mg (n=28), 300 mg (n=5), and 350 mg (n=11). Seven dose-limiting toxicities were observed in six (3%) patients who received 150 mg, 225 mg, or 350 mg nazartinib once daily. Although the maximum tolerated dose was not met, the recommended phase 2 dose was declared as 1...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Conclusions: Camrelizumab administration combined with MWA was safe in the treatment of advanced NSCLC, and the combination improved the ORR of camrelizumab alone compared to previous reports.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
The aim of this study was to determine the role of physiological measurements in the evaluation of postoperative risks before lung cancer surgery. Spirometry and ABG were performed for all patients with NSCLC before operation. Diffusion test and CPET were performed to patients with moderate-high risk for operation and the patient who required pneumonectomy. Postoperative complications, mortality and duration of stay in ICU and hospital were recorded.115 NSCLC patients who had limited lung capacity(22F,93M) with a mean age of 62.37±10.11 were included prospectively between Jan2015-Dec2018. 54(46.9%) patients were acc...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Thoracic surgery Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Pneumonia | Study